Research programme: anticancer and antiviral therapeutics - MultiCell Technologies

Drug Profile

Research programme: anticancer and antiviral therapeutics - MultiCell Technologies

Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485

Latest Information Update: 27 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MultiCell Technologies Inc
  • Developer MultiCell Technologies Inc; University Health Network
  • Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Hepatocellular carcinoma; Viral hepatitis

Most Recent Events

  • 25 Aug 2014 Pharmacodynamics data from preclinical studies in Cancer and Viral hepatitis released by MultiCell Technologies
  • 01 Aug 2014 Preclinical trials in Viral hepatitis in USA (Parenteral)
  • 15 Jan 2014 Preclinical trials in Hepatocellular carcinoma in USA before January 2014 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top